Compare · ABSI vs CRL
ABSI vs CRL
Side-by-side comparison of Absci Corporation (ABSI) and Charles River Laboratories International Inc. (CRL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and CRL operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $11.14B, about 7.0x ABSI ($1.59B).
- Over the past year, ABSI is up 299.2% and CRL is up 49.8% - ABSI leads by 249.4 points.
- ABSI has been more active in the news (9 items in the past 4 weeks vs 2 for CRL).
- CRL has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- Charles River Laboratories International Inc.
- Price
- $10.24+0.10%
- $231.30+0.67%
- Market cap
- $1.59B
- $11.14B
- 1M return
- +57.54%
- +23.25%
- 1Y return
- +299.22%
- +49.83%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2000
- News (4w)
- 9
- 2
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest ABSI
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Chief Executive Officer Mcclain Sean covered exercise/tax liability with 59,896 shares, decreasing direct ownership by 0.69% to 8,655,555 units (SEC Form 4) (for tax liability)
- SEC Form 8-K filed by Absci Corporation
- SEC Form 424B5 filed by Absci Corporation
- Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
- Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits
- Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
- The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Latest CRL
- Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
- Director Foster James C sold $16,875,000 worth of shares (75,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 31,596 units (SEC Form 4)
- Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
- Charles River upgraded by Morgan Stanley with a new price target
- Director Foster James C gifted 183,361 shares and received a gift of 183,361 shares, decreasing direct ownership by 62% to 106,596 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit gifted 3,386 shares and received a gift of 3,386 shares, decreasing direct ownership by 9% to 36,013 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M gifted 1,529 shares and received a gift of 1,529 shares, decreasing direct ownership by 13% to 9,853 units (SEC Form 4)
- Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)
- EVP & Chief Financial Officer Coleman Glenn was granted 6,640 shares, increasing direct ownership by 31% to 27,752 units (SEC Form 4)
- EVP, Chief Information Officer Mintz Mark was granted 2,534 shares and covered exercise/tax liability with 369 shares, increasing direct ownership by 29% to 9,546 units (SEC Form 4)